Skip to main content

Zura Bio Ltd

For the period ended Sep 30, 2024. Filed Nov 7, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 7, 2024

ZURA$1.41+13.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations

(Unaudited)

(In thousands, except share and per share data)

​​​​​​​​​​​​​
​ · ​ · For the Three Months Ended · ​ · For the Nine Months Ended
​ · ​ · September 30, · ​ · September 30,
​ · 2024 · 2023 · 2024 · 2023
Operating expenses: · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​
Research and development​$6,029​$3,965​$15,161​$37,079
General and administrative​​13,290​​6,222​24,296​14,732
Total operating expenses​​19,319​​10,187​39,457​51,811
Loss from operations​​(19,319)​​(10,187)​(39,457)​(51,811)
Other (income)/expense, net:​​​​​​​​​​​​
Other (income)/expense, net​​(22)​​4​​(47)​​7
Interest income​​(2,461)​​(815)​​(5,872)​​(816)
Dividend income​​—​​(987)​​—​​(1,392)
Change in fair value of private placement warrants​​3,866​​(119)​​5,240​​236
Change in fair value of note payable​​—​​—​​—​​2,244
Total other (income)/expense, net​​1,383​​(1,917)​​(679)​​279
Loss before income taxes​​(20,702)​​(8,270)​​(38,778)​​(52,090)
Income tax benefit​​—​​—​​—​​—
Net loss before redeemable noncontrolling interest​​(20,702)​​(8,270)​​(38,778)​​(52,090)
Net loss attributable to redeemable noncontrolling interest​​—​​—​​—​​203
Net loss​​(20,702)​​(8,270)​​(38,778)​​(51,887)
Accretion of redeemable noncontrolling interest to redemption value​​(2,240)​​—​​(4,577)​​(203)
Deemed dividend to redeemable noncontrolling interest​​—​​—​​—​​(10,875)
Adjustment of redeemable noncontrolling interest from redemption value to carrying value​​—​​—​​7,017​​—
Net loss attributable to Class A Ordinary Shareholders of Zura​$(22,942)​$(8,270)​$(36,338)​$(62,965)
Net loss per share attributable to Class A Ordinary Shareholders of Zura, basic and diluted​$(0.26)​$(0.18)​$(0.52)​$(2.22)
Weighted-average Class A Ordinary Shares used in computing net loss per share attributable to Class A Ordinary Shareholders of Zura, basic and diluted​​87,335,667​​46,876,344​69,778,401​28,402,487

For the Three Months Ended September 30, 2024

​​​​​​​​​​​​​​​​​​​​​​​​​​​
​ · ​ · Redeemable · ​ · Convertible · ​ · ​ · Class A · ​ · Additional · ​ · ​ · ​ · ​ · ​ · ​ · Total
​ · ​ · Noncontrolling · ​ · Preferred Shares · ​ · ​ · Ordinary Shares · ​ · Paid-in · ​ · Accumulated · ​ · Noncontrolling · ​ · Shareholders’
​ · Interest · Shares · Amount · Shares · Amount · Capital · Deficit · Interest · Equity
Balance as of June 30, 2024$14,000​—​$—​63,683,806​$6​$278,086​$(121,570)​$1,541​$158,063
Issuance of Pre-Funded Warrants in exchange for Class A Ordinary Shares​​—​—​​—​​(4,000,000)​​—​​—​​—​​—​​—
Issuance of Class A Ordinary Shares in exchange for Private Placement Warrants​—​—​—​1,718,108​—​​6,230​—​​—​6,230
Issuance of Class A Ordinary Shares in exchange for Public Warrants​—​—​—​2,064,082​—​​—​—​​—​—
Issuance of Class A Ordinary Shares in connection with a sale under the ATM, net of $0.2 million of commissions​—​—​—​1,500,000​1​​5,533​—​​—​5,534
ATM transaction costs​​—​—​​—​​—​​—​​(626)​​—​​—​​(626)
Issuance of Class A Ordinary Shares for restricted stock units, net of shares withheld for taxes​​—​—​​—​​327,534​​—​​(318)​​—​​—​​(318)
Share-based compensation​​—​—​​—​​—​​—​​8,646​​—​​—​​8,646
Accretion of redeemable noncontrolling interest to redemption value​​2,240​—​​—​​—​​—​​(2,240)​​—​​—​​(2,240)
Net loss​​​​—​​—​​—​​—​​​​​(20,702)​​—​​(20,702)
Balance as of September 30, 2024​$16,240​—​$—​​65,293,530​$7​$295,311​$(142,272)​$1,541​$154,587

For the Three Months Ended September 30, 2023

​​​​​​​​​​​​​​​​​​​​​​​​​​​
​ · ​ · Redeemable · ​ · Convertible · ​ · ​ · Class A · ​ · Additional · ​ · ​ · ​ · ​ · ​ · ​ · ​ · Total
​ · ​ · Noncontrolling · ​ · Preferred Shares · ​ · ​ · Ordinary Shares · ​ · Paid-in · ​ · Accumulated · ​ · Noncontrolling · ​ · Shareholders’
​ · Interest · Shares · Amount · ​ · ​ · Shares · Amount · ​ · Capital · Deficit · Interest · Equity
Balance as of June 30, 2023​$20,875​—​$—​​43,593,678​$4​$155,654​$(86,751)​$1,541​$70,448
Share-based compensation​​—​—​​—​​—​​—​​2,577​​—​​—​​2,577
Net loss​—​—​—​—​—​​—​(8,270)​​—​(8,270)
Balance as of September 30, 2023$20,875​—​$—​43,593,678​$4​$158,231​$(95,021)​$1,541​$64,755

For the Nine Months Ended September 30, 2024

​​​​​​​​​​​​​​​​​​​​​​​​​​​
​ · Redeemable · Convertible Preferred · Class A · Additional · ​ · ​ · ​ · ​ · ​ · Total
​ · ​ · Noncontrolling · ​ · Shares · ​ · ​ · Ordinary Shares · ​ · Paid-in · ​ · Accumulated · ​ · Noncontrolling · ​ · Shareholders’
​ · Interest · Shares · Amount · Shares · Amount · Capital · Deficit · Interest · Equity
Balance as of December 31, 2023​$18,680—​$—​43,593,678​$4​$162,820​$(103,494)​$1,541​$60,871
Issuance of Class A Ordinary Shares in connection with April 2024 Private Placement, net of $7.2 million of transaction costs​——​—​20,090,128​2​55,221​—​​—​55,223
Issuance of Pre-Funded Warrants in connection with April 2024 Private Placement​​—​—​​—​​—​​—​​50,030​​—​​—​​50,030
Issuance of Pre-Funded Warrants in exchange for Class A Ordinary Shares​​—​—​​—​​(4,000,000)​​—​​—​​—​​—​​—
Issuance of Class A Ordinary Shares in exchange for Private Placement Warrants​​—​—​​—​​1,718,108​​—​​6,230​​—​​—​​6,230
Issuance of Class A Ordinary Shares in exchange for Public Warrants​​—​—​​—​​2,064,082​​—​​—​​—​​—​​—
Issuance of Class A Ordinary Shares in connection with a sale under the ATM, net of $0.2 million of commissions​​—​—​​—​​1,500,000​​1​​5,533​​—​​—​​5,534
ATM transaction costs​​—​—​​—​​—​​—​​(626)​​—​​—​​(626)
Issuance of Class A Ordinary Shares for restricted stock units, net of shares withheld for taxes​​—​—​​—​​327,534​​—​​(318)​​—​​—​​(318)
Share-based compensation​​—​—​​—​​—​​—​​13,981​​—​​—​​13,981
Adjustment of redeemable noncontrolling interest from redemption value to carrying value​​(7,017)​—​​—​​—​​—​​7,017​​—​​—​​7,017
Accretion of redeemable noncontrolling interest to redemption value​​4,577​—​​—​​—​​—​​(4,577)​​—​​—​​(4,577)
Net loss​——​—​—​—​—​(38,778)​​—​(38,778)
Balance as of September 30, 2024​$16,240—​$—​65,293,530​$7​$295,311​$(142,272)​$1,541​$154,587

For the Nine Months Ended September 30, 2023

​​​​​​​​​​​​​​​​​​​​​​​​​​​
​ · Redeemable · Convertible Preferred · Class A · Additional · ​ · ​ · ​ · ​ · ​ · Total
​ · ​ · Noncontrolling · ​ · Shares(1) · ​ · ​ · Ordinary Shares(1) · ​ · Paid-in · ​ · Accumulated · ​ · Noncontrolling · ​ · Shareholders’
​ · Interest · Shares · Amount · Shares · Amount · Capital · Deficit · Interest · Equity (Deficit)
Balance as of December 31, 2022​$10,00013,510,415​$12,500​279,720​$—​$—​$(32,056)​$—​$(32,056)
Issuance of Series A-1 convertible preferred shares as license compensation​—267,939​2,186​—​—​—​—​​—​—
Conversion of Series A-1 convertible preferred shares to Class A Ordinary Shares in connection with Business Combination​—(13,778,354)​(14,686)​13,778,354​2​14,684​—​​—​14,686
Issuance of Class A Ordinary Shares in connection with Business Combination, including PIPE Investment, Forward Purchase Investment, and Backstop Shares, net of $4.0 million of transaction costs​​—​—​​—​​12,444,081​​1​​48,350​​—​​—​​48,351
Issuance of Class A Ordinary Shares to settle research and development license consideration liability​​—​—​​—​​550,000​​—​​4,488​​—​​—​​4,488
Reclassification of public warrant liability to equity​​—​—​​—​​—​​—​​2,001​​—​​—​​2,001
Issuance of Class A Ordinary Shares in connection with April 2023 Private Placement, net of $9.8 million of transaction costs​​—​—​​—​​15,041,530​​1​​54,133​​—​​—​​54,134
Issuance of Pre-Funded Warrants in connection with April 2023 Private Placement​​—​—​​—​​—​​—​​16,070​​—​​—​​16,070
Issuance of Class A Ordinary Shares to Lilly in connection with 2023 Lilly License​​—​—​​—​​1,000,000​​—​​7,840​​—​​—​​7,840
Issuance of restricted share awards​​—​—​​—​​499,993​​—​​—​​—​​—​​—
Share-based compensation​​—​—​​—​​—​​—​​10,665​​—​​—​​10,665
Net loss​​(203)​—​​—​​—​​—​​—​​(51,887)​​—​​(51,887)
Accretion of redeemable noncontrolling interest to redemption value​​203​—​​—​​—​​—​​—​​(203)​​—​​(203)
Stone Peach Call Right issued to noncontrolling interest​​—​—​​—​​—​​—​​—​​—​​1,541​​1,541
Deemed dividend to redeemable noncontrolling interest​​10,875​—​​—​​—​​—​​—​​(10,875)​​—​​(10,875)
Balance as of September 30, 2023​$20,875​—​$—​​43,593,678​$4​$158,231​$(95,021)​$1,541​$64,755

(1) The Company’s convertible preferred shares and Class A Ordinary Shares prior to the closing of the Business Combination (as defined in Note 1) have been retroactively restated to reflect the exchange ratio of approximately 108.083 established in the Business Combination Agreement as described in Note 6.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.